Company / Net Income
Corbus Pharmaceuticals Holdings, Inc. Net Income History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$45.6M
FY2022
5-year range
-$111.3M / -$32.4M
FY2018-FY2022
Trend
+59.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income returned to growth in FY2022 after 4 years of decline, reaching -$46M.
Based on SEC 10-K filings.
-$46M in FY2022.
Improved from -$71M to -$46M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, net income increased 59.0% year-over-year.
- Peak net income was recorded in FY2015.
- Lowest net income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$45.6M | +59.0% |
| FY2021 | -$111.3M | -55.7% |
| FY2020 | -$71.5M | -28.3% |
| FY2019 | -$55.7M | -71.7% |
| FY2018 | -$32.4M | -266.3% |
| FY2017 | -$8.9M | +0.0% |
| FY2016 | -$8.9M | -248.4% |
| FY2015 | -$2.5M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026